Introduction
Radiotherapy is one of the primary cancer treatment modalities. It also provides a promising means of targeting the activation of anti-tumour gene therapy vectors. Gene promoters activated by clinical doses of ionizing radiation (IR) can provide suitable control over the expression of therapeutic genes. Several groups have utilized enhancer/promoters of radiation-responsive genes (eg early growth response 1 or Egr1 and p21/WAF1) to drive the expression of heterologous genes, including some specifically for anti-tumor therapy. [1] [2] [3] [4] [5] To improve the activation response of cancer gene therapy vectors to IR doses of clinical relevance, we constructed a synthetic gene enhancer consisting of short DNA motifs of sequence CC(A/T) 6 GG (CArG elements) derived from the Egr1 gene. 6 The new enhancer was shown to be more IR-responsive than the native Egr1 enhancer when tested in the same vector context, in MCF-7 breast adenocarcinoma cells. This synthetic 'CArG' promoter was then used to regulate expression of the herpes simplex virus thymidine kinase (HSVtk) suicide gene in experimental genedirected enzyme prodrug therapy (GDEPT) assays. Following irradiation with a single 1-5 Gy dose, cell cultures grown in the presence of the prodrug ganciclovir (GCV) showed significantly greater growth inhibition compared with single-treatment controls. 6 Previous studies have demonstrated that the binding of serum response factor (SRF) to CArG elements (known also as serum response elements or SREs) in the promoters of several genes, such as Egr1, c-fos and members of the actin family, led to an increase in gene expression. 7, 8 A number of accessory proteins (eg p62/TCF, SAP-1 and Elk-1) have been shown to complex with SRF during this process.
9-11 SRF-mediated gene regulation occurs, for example, following mitogenic stimulation of cells by phorbol esters contained in serum. Stimuli-driven activation of the Egr1 promoter has been shown to require phoshorylation by mitogen-activated protein (MAP) kinases, which are often triggered by cellular stresses such as radiation. 12, 13 The above findings strongly suggest that SRF complexes play a central role in CArG-mediated, IR-induced activation of Egr1.
Despite some success in experimental GDEPT using the native Egr1 enhancer, [14] [15] [16] [17] there is scope to both improve and tailor the activation responses of CArG pro-moters to clinical IR doses. Prior work using deletion mutants of the Egr1 gene promoter, demonstrated that multiple CArG elements gave greater inducibility by serum and specific growth factors than single units. 8 Where more than one CArG unit is present in a native gene promoter, they are often of different sequence though fitting the overall CC(A/T) 6 GG consensus. [18] [19] [20] There is evidence that some of these CArG elements are more responsive than others to serum and cellular growth factors 8 and also radiation. 1 DNAase protection assays conducted on CArG-containing DNA fragments bound with SRF revealed that SRF/coactivator complex binding, although centered on the dyad, extended by up to 10 nucleotides beyond the CArG motif. 21 Furthermore, self-regulation of SRF expression via CArG elements in the SRF gene promoter was enhanced by the presence of a binding site for the Sp1 transcription factor. 22 In the present study, CArG numbers, core sequences, spacing and context were specifically altered in an attempt to increase enhancer sensitivity to low doses of ionizing radiation and define parameters important for future promoter development. Lastly, in vitro and in vivo GDEPT assays were used to demonstrate the efficacy of new generation suicide gene vectors containing the improved promoters.
Results

Influence of CArG element numbers on promoter response
To determine the effect that increasing CArG element number would have on the inducibility of synthetic promoters to ionizing radiation (IR), our standard green fluorescent protein (GFP) reporter assay was employed. 6 In addition to the previously described CArG promoter (containing four directly-repeated elements of identical sequence; E4), 6 new promoters (denoted E6, E9, E12) were tested, carrying six, nine and 12 tandem-repeat copies of the prototype CArG sequence (CCTTATTTGG). Reporter plasmids containing the novel promoter constructs were then transiently transfected into MCF-7 cells, and promoter activity assayed following a single 3 Gy dose. Results showed that increasing the number of elements from four to six and then nine produced a concurrent increase in IR-inducibility ( Figure 1) . However, the E12 promoter was found to be less inducible than E9, showing results similar to E4 and E6. This response trend was seen in all individual experiments. When pooled the results revealed mean fold-induction rates of 1.95 (± 0.17), 2.29 (± 0.13), 2.74 (± 0.17) and 1.98 (± 0.12) for E4, E6, E9 and E12 respectively ( Figure 1 ). As expected, the parental vector pCIneo, showed no notable fluorescence before or after irradiation (indicated by a fold-induction of 0.64 ± 0.19). Likewise, the strong constitutive cytomegalovirus immediate-early (CMV IE) gene promoter, although producing high basal levels of GFP expression, showed a negligible increase on irradiation (1.27 ± 0.12 foldinduction). Statistical analysis of the pooled results demonstrated a significant (P Ͻ 0.05, Student's t test) improvement of the E9 promoter over both the E4 prototype and the other novel CArG promoters.
Altering CArG element sequences and spacing
To study the effect of CArG sequence alteration on the IR-induction response, two new test vectors were pro-
Figure 1 Radiation-mediated activation of gene promoters. MCF-7 cells were transiently-transfected (~20% efficiency) with plasmid constructs bearing the test promoters upstream of the coding region for the enhanced green fluorescent protein (GFP). Fold increase in GFP expression following a single 3 Gy dose was measured by FACS assay~40 h after irradiation. The synthetic promoters tested were as follows: E4, E6, E9 and E12 contained four, six, nine and 12 directly repeated CArG elements of the prototype sequence CCTTATTTGG. E6, ns1 and ns2 also contained six directly repeated CArG elements, but of different core A/T sequence. E6, s6, s10 and s18 contained six CArG elements of the above prototype sequence, but with inter-element spacing of zero, six, 10 and 18 nucleotides, respectively. Sp1 is the E6 promoter with an adjacent Sp1 transcription factor binding site. The pCIneo parent plasmid (pCI) and the CMVregulated GFP plasmid (CMV) served as controls.
duced (pE6ns1, pE6ns2), each containing enhancers with six directly-repeated CArG elements in which the A/T core sequences differed from the prototype. These new sequence (ns) CArG motifs are also present in the native Egr1 promoter (ns1, CCATATTAGG; ns2, CCATATAAGG).
The first new enhancer (E6-ns1) did not show a significantly different IR response than that containing the prototype CArG sequence (E6), with respective foldinductions of 1.71 (± 0.23) and 1.87 (± 0.20) in MCF-7 cells, following a single 3 Gy radiation dose ( Figure 1 ). However, E6-ns2 gave a substantially higher induction level (2.96 ± 0.51) under the same conditions.
To examine how the spatial arrangement of CArG elements might affect IR-responsiveness, another series of enhancers was constructed. In these vectors, the prototype CArG element sequences in the E6 enhancer (E6) were each separated by six, 10 or 18 nucleotide 'spacer' sequences (also derived from inter-CArG sequences in the Egr1 enhancer), producing the plasmid constructs E6-s6, E6-s10 and E6-s18. Nevertheless, reporter assays in MCF-7 cells showed that the addition of these spacers had negligible/little effect on IR-responsiveness. A single 3 Gy dose produced fold-increases of GFP expression of 1.75 ± 0.22 (E6-s6), 1.61 ± 0.28 (E6-s10) and 1.65 ± 0.28 (E6-s18), compared with 1.71 ± 0.23 for the prototype E6 enhancer (Figure 1) .
To test whether an Sp1 binding site adjacent to CArG elements would influence IR-activation, we inserted an Sp1 site and intervening sequences derived from the SRF promoter directly upstream of the E6 enhancer. However, this 'Sp1-E6' enhancer proved to be no more responsive than the E6 prototype, with fold IR-induction rates of 1.52 ± 0.12 and 1.71 ± 0.23, respectively (Figure 1 ).
Once CArG number and sequence were defined as important factors in IR-response, an enhancer combining both these features was made. The new construct (E9-ns2) had nine CArG elements of the sequence CCATA-TAAGG. The IR-induction of E9-ns2 was compared with both the prototype E4 and the native Egr1 (N) enhancers, with the CMV IE promoter again as a control. After a single 3 Gy dose, the fold-increase of GFP expression in MCF-7 cells, mediated by wild-type enhancer N was 1.44 ± 0.08, significantly higher at 2.24 ± 0.15 for E4 and greatest at 2.94 ± 0.10 for E9-ns2 ( Figure 2 ). As expected, the CMV promoter construct produced no increase in GFP expression on irradiation (1.14 ± 0.13-fold induction). Finally, the basal (ie unirradiated) expression of the constructs was examined. The number of transfected cells classified as GFP positive by fluorescence was 23.2% (± 0.06) for the CMV construct, 4.5% (± 0.25) for the native Egr1 enhancer (N), 2.9% (± 0.42) for E4 and lowest for E9-ns2 at 2.2% (± 0.02). Thus the synthetic enhancers were notably less 'leaky' than the native promoter and the more IR-sensitive E9-ns2 CArG enhancer actually exhibited the least non-specific reporter expression.
In vitro GDEPT assays
Having determined that both CArG element number and sequence significantly altered IR-induction responses by GFP assay, the most responsive test promoters (E9 and E9ns2) were then used for experimental GDEPT in MCF-7 and U373-MG tumor cells. The HSVtk/GCV suicide gene system was employed, but using the more effective mutant 30 gene variant, which has been shown to be more effective in GDEPT then the wild-type due to greater GCV affinity. 23 The prototype E4 promoter was also included for comparative purposes. 6 Cell survival following irradiation and GCV exposure was measured by MTS growth delay assay. Untreated, unmodified (parent) cells were defined as 100% survival. Exposure of unmodified and plasmid-transfected MCF-7 cell samples to GCV did not significantly reduce cell survival ( Figure  3 ). Thus basal (not IR-induced) HSVtk expression from the test promoters (leading to GCV-mediated cell death) was undetectable. As expected, a single 3 Gy irradiation dose reduced cell survival. For MCF-7 cells this was to 82.3 ± 2.0%, and 88.2 ± 2.4% for U373-MG, with similar values for transfected cell populations. The addition of GCV to the irradiation treatment had no significant effect on unmodified cells, with survivals of 80.7 ± 2.4% and 91.7 ± 1.1% for MCF-7 and U373-MG, respectively. However, for plasmid-transfected cells survival was reduced to 71.7 ± 2.2% for the E4 enhancer, 65.7 ± 1.2% for E9 and 61.9 ± 1.7% for E9-ns2. The same trend was seen for U373-MG cells, though with generally lower levels of cell kill (Figure 3) . Plasmid transfection efficiencies were~20% in MCF-7 and 10-15% for U373 cells.
Thus these GDEPT experiments demonstrate that the nine CArG-element promoters were more effective at driving IR-responsive gene expression than both the prototype E4 and native Egr1 promoter, with E9-ns2 showing the best response.
Promoter function in vivo
In order to test whether synthetic CArG promoters were IR-inducible in an in vivo context, an established nude mouse U87-MG glioblastoma xenograft model was employed. Preliminary, qualitative assessments were conducted using GFP reporter constructs. Xenografts were established using stable cell lines containing the prototype pE4GFP plasmid. When the tumors had reached~3 mm in diameter, they were irradiated with 3 × 3 Gy (24 h intervals). After a further 48 h, the tumors were excised and examined by fluorescent microscopy. GFP fluorescence was clearly visible in irradiated
Figure 3 IR-mediated experimental GDEPT using synthetic CArG promoters. MCF-7 and U373MG (parent) tumor cells were transiently transfected with plasmid constructs containing the HSVtk coding region under control of enhancers containing four (E4) and nine (E9) prototype sequence CArG elements or nine CArGs of new sequence (E9ns2). For each transfectant, four subsequent treatments are shown; shamirradiation/no GCV, sham-irradiation/GCV, irradiation/no GCV and single 3 Gy irradiation/GCV. Growth inhibition (MTS assay) is shown as % regrowth (growth fraction) of treated cultures.
samples, with none apparent in unirradiated control tumors (data not shown). To determine promoter utility in GDEPT, the same model was adopted, using the E9 promoter to drive HSVtk expression. Tumors were permitted to grow to a diameter of~3 mm then irradiated (3 × 5 Gy) or sham-treated, with or without systemic GCV administration (see Materials and methods for experimental details). For the parental U87-MG tumors, GCV inoculation did not affect the regrowth of shamirradiated tumors. The mean time taken to reach a tumor volume of 500 mm 3 following sham-irradiation was 17.3 ± 4 days compared with 15.4 ± 6 days when GCV was also given. As expected, irradiation increased this regrowth time to a mean of 47.6 ± 7 days, and GCV administration did not significantly affect this (44.5 ± 9 days). For sham-irradiated U87-MG/pE9HSVtk xenografts, mean tumor regrowth time was again unaffected Gene Therapy by GCV treatments (8.4 ± 1 day with no GCV and 9.6 ± 3 days with GCV). However, compared with the results obtaining using U87-MG xenografts, GCV caused a significant tumor regrowth delay for irradiated U87-MG/pE9HSVtk tumors. Mean regrowth times for irradiated tumors containing pE9HSVtk were 33.4 ± 5 days without GCV and 44.3 ± 4 days when combined with GCV treatment (statistical significance P Ͻ 0.01, Wilcoxon rank sum test). Thus, only when the IR-responsive suicide gene construct was present in the tumor was GCV able to enhance radiation treatment. These results demonstrate that IR-responsive CArG promoters function in vivo as well as in vitro.
Discussion
The promoter sequence motif CC(A/T) 6 GG, known as the CArG element, has been shown to have a pivotal role in the radiation-induced expression of the Egr1 gene. 1 This response is mediated, at least in part, by reactive oxygen species produced by ionizing radiation and oxidative chemicals such as hydrogen peroxide. 24 The precise mechanism of this response, and the transcription factors interacting with CArG elements, has yet to be elucidated. However, complexes of phosphorylated transcription factors and accessory proteins, including serum response factor (SRF), are known to promote gene expression by binding to CArG motifs (also known as serum response elements or SREs). This has been noted in the promoters of the Egr1 (previously known as zif 268) and c-fos genes, both of which are IR-responsive. 8, 25 Egr1 enhancer deletion studies also showed that multiple CArG elements conferred greater promoter inducibility than single elements to both SRF and IR. 1, 8 In the current study, involving the assay of a series of synthetic promoter constructs, we demonstrate that increasing the numbers of tandemly repeated CArG elements in the test enhancer from four to six and then to nine improves the induction response to low doses of radiation. This may be by simply providing more target sequences, presented in a suitably accessible configuration, for the efficient binding of specific transcription factor complexes, thus driving gene expression. However, when the 12 CArG element enhancer was used, the IR-response was no more than for four and six units. Thus, the continual addition of CArG elements may not necessarily increase enhancer IR-response. X-ray crystallographic studies have shown that the binding of SRF to CArG sequences causes 'bending' of the DNA helix as it wraps around the protein. 26 Cumulative changes in secondary structure caused by occupancy of multiple binding sites, although initially increasing corresponding gene expression, might eventually lead to down-regulation. In this case, sufficient spacing between elements may alleviate this restriction. Interestingly, the influence of responsive element number has also been reported in studies using DNA sequences responsive to hypoxia (hypoxia responsive elements; HREs). For example, although no significant difference in induction response was observed when the number of HREs (from the erythropoietin gene) was increased from three to six copies, an increase to nine copies had a marked positive effect. 27 Conversely, a saturation effect was seen when more than five copies of the vascular endothelial growth factor HRE were employed in test promoters. 28 Further-more, in our recent studies involving hypoxia-induction of synthetic HRE enhancers derived from phosphoglycerate kinase 1 promoter sequences, the use of 10 directrepeat units was found to be less inducible than five. 29 Interestingly, our results also reveal that increasing the number of CArG elements in the synthetic promoters does not lead to a corresponding increase in non-specific gene expression. Conversely, synthetic enhancers with more IR-responsive units showed progressively less 'leakiness' under non-irradiated conditions, all of which were less than for the native Egr1 enhancer. Indeed, the in vivo data reveal no detectable leakiness (no increased GCV-mediated cell kill for U87-MG/E9HSVtk compared with parental U87-MG xenografts). In a clinical setting, this important finding could considerably enhance differential expression of a suicide gene delivered to the irradiated tumor mass compared with any vector DNA delivered to the surrounding unirradiated tissue.
Our data on the influence of CArG sequence on IRresponse reveal that different elements, although fitting to the CC(A/T) 6 GG consensus motif, exhibit diverse levels of inducibility. Previous studies on the affinity of SRF binding to oligonucleotides bearing various CArG elements, showed distinct differences depending on the precise A/T core sequences. 8, 30 Specifically, the ATATAA core sequence (equivalent to our ns2) was found to have more SRF affinity than the ATATTA core sequence (ns1 in this study, also known to be IR-responsive in the cfos SRE) in concordance with the IR-responses presented here. Datta et al 1 also showed that the three proximal CArG elements in the native Egr1 promoter did not contribute to the IR response, in contrast to the three distal elements. Similarly, both our prototype and ns2 CArG sequences are identical in sequence to distal Egr1 CArGs. Nevertheless, the ns1 element, which we also found to be IR-responsive, has the same sequence as one of the proximal, reportedly non-responsive units in the native Egr1 promoter. 1 However, the ns1 CArG sequence was shown to be the SRF-responsive in an earlier study. 8 Thus it is possible that sequence context and spatial positioning may be important in dictating CArG responses.
With a view to reducing potential steric hindrance between transcription factor complexes binding to CArG elements, we introduced 'spacer' sequences between the units to determine if this could enhance IR-response. It is noteworthy that DNAse protection experiments carried out on the c-fos SRE demonstrated that SRF binds asymmetrically, engaging the DNA over a region, which extends approximately 10 bases upstream and 4 bases downstream of the CArG motif. 7, 21 However, in this study the introduction of up to 18 nucleotides between units in our synthetic promoter did not improve IRinducibility. It is possible that even 18 bp may not be sufficient inter-element spacing for transcription factor complexes to bind to adjacent CArG units, particularly if binding causes bending of the DNA helix, as is the case for SRF. 26 For native enhancers (eg c-fos) multiple CArG elements may be unnecessary for efficient function. Those genes that possess several units (eg Egr1) display notable inter-element spacing, with no more than two CArG motifs in close proximity (eg 6 bp 18, 20 ) . Further work will be needed to determine if IR-responses for synthetic CArG enhancers could be further improved with an increase in element spacing in line with that seen in the native promoters (eg 28 bp in Egr1). The sequence surrounding CArG motifs appears to have little importance in determining activity status. In native promoters, the sequence around active units varies considerably, and even studies with synthetic targets for SRF showed that it was the CArG consensus rather than adjacent sequences which were critical to binding. 31 The expression of the SRF gene itself is also partially self-regulated via CArG elements situated in its own promoter. 19 However, maximal serum responsiveness requires the presence of the Sp1 binding site immediately adjacent to one of the three CArG elements. 22 The Egr1 promoter contains several potential Sp1 binding sites, one of which is located between two IR-responsive CArG elements. Nevertheless, the placing of an Sp1 binding site in the E6 synthetic promoter (using the identical spacing and sequence context seen in the SRF promoter) did not yield an increase in IR-response.
Finally, GDEPT experiments with the synthetic promoters agreed with the results of the GFP reporter assays. The in vitro studies also showed that both the number of CArG elements and their core A/T sequences were important factors in determining promoter response to low IR doses. As anticipated, the animal model data reveal that synthetic CArG promoters also function in vivo, and are able to significantly contribute to tumor growth control through IR-mediated regulation of a GDEPT system. Although in vitro and in vivo CArG promoter effects are quantitatively modest (though apparently with little basal expression), if combined with an appropriate expression amplification and maintenance system such as described in Scott et al, 32 the resultant level of therapeutic product expression could be sufficient to elicit high-level tumor cytotoxicity. By this system, following activation of the vector via the IR-responsive promoter, the role of regulating therapeutic gene expression is 'transferred' to another promoter. In our previous study, 32 the strong, constitutive CMV IE promoter drove suicide gene expression, however additional levels of control could be achieved by using alternative promoters (eg cell type specific). Consequently, even following a systemic vector delivery, only vector molecules delivered to the correct target cell type, which also fall within the irradiated field would be activated during radiotherapy. We believe a new generation of 'radiogenetic' suicide gene vectors based upon these principles has great potential in the future of radiotherapeutic treatments for a wide range of cancer conditions.
Materials and methods
Cell culture and transfection
Human MCF-7 mammary adenocarcinoma, U87-MG and U373-MG glioblastoma cells (European Collection of Cell Cultures, Salisbury, UK) were maintained in RPMI medium (Life Technologies, Paisley, UK) supplemented with 10% fetal calf serum, 2 mM L-glutamine (Life Technologies), and incubated in a humidified incubator at 37°C in 5%O 2 :5%CO 2 :90%N 2 . Cells were routinely tested and found free of mycoplasma infection (MycoTect kit, Life Technologies). Transient cell transfectants for all plasmid constructs were produced by using Lipofectamine (Life Technologies) by the method described in Ref. 6 , when cells were at~60% confluence. In each experiment, a plasmid in which the CMV IE gene promoter controlled GFP reporter gene expression was used to determine transfection efficiency. The U87-MG/pE9HSVtk cell line used in tumor xenografts was established by initial plasmid transfection followed by enrichment in neomycin (0.5 mg/ml) to ensure each cell in the population carried the construct. toneal injections twice daily for 10 days. The tumors in the vehicle-control group were similarly injected with PBS alone. Animals from each GCV dosing group were then randomly divided in radiation or sham-irradiation treatment cohorts. On days 3, 4 and 5 of GCV/vehicle dosing, the animals were placed in a lead restraining jig apparatus (to shield the animal) and the tumor volume irradiated with 5 Gy of 240 kVp X-rays or 'shamirradiated' (jigged, placed on the X-ray set for the standard period, but not irradiated). Tumor size was determined in three planes using calipers, twice weekly throughout the experiment. 33 Individual tumor growth rates and volumes were then mathematically determined by polynomial fitting.
